Ep. 384 - Back to School Special: The global FIH trials race
From BioCentury This Week · · 42 min
This plays from the publisher's own server. We do not host a copy.
Description
China has changed the global narrative on delivering early human clinical data, with a new bar for speed and efficiency. And now drug developers and policymakers around the world have gotten the message and know that this is no time for complacency. On a special edition of the BioCentury This Week podcast, BioCentury's analysts discuss why transformational reform for early clinical development will require rethinking the risk-control paradigm for first-in-human trials. It’s the subject of the 2026 Back to School issue (https://www.biocentury.com/article/660470), the 34th edition of an annual analysis that takes on one of the most pressing topics facing the biopharma industry.
View full story: https://www.biocentury.com/article/660629
#ClinicalTrials #FirstInHuman #DrugDevelopment #FDA #BiopharmaPolicy
0:00 - Introduction 6:40 - U.S. 15:09 - Australia 24:00 - China 32:14 - Europe
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)